Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes

Sun, Baoqing; Ma, Teng; Li, Yalin; Yang, Ni; Li, Bohai; Zhou, Xin‐Fu; Guo, Shuai; Zhang, Shukun; Kwok, Lai‐Yu; Sun, Zhihong; Zhang, Heping

doi:10.1128/msystems.00100-22

Cited by 47 publications

(28 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these microbes are part of the normal gut microbiota, they might act as opportunistic pathogens under suboptimal conditions. Oscillibacter -like organisms are thought to be associated with high-fat-diet-induced gut dysfunction, possibly via disrupting the gut barrier integrity in the proximal colon [ 53 ]; Hungatella hathewayi has been found to advance intestinal tumorigenesis via regulating multiple tumor suppressor gene promoters on the epigenetic level [ 54 ]; Eubacterium rectale could initiate colorectal cancer through promoting colon inflammation [ 55 ]. Therefore, one possible mechanism of the tumor suppressor effect of Probio-M9 is inhibiting certain opportunistic microbes in the gut environment in mammary tumor-bearing mice.…”

Section: Discussionmentioning

confidence: 99%

Lacticaseibacillus rhamnosus Probio-M9-Driven Mouse Mammary Tumor-Inhibitory Effect Is Accompanied by Modulation of Host Gut Microbiota, Immunity, and Serum Metabolome

Zhang

et al. 2022

Nutrients

Self Cite

View full text Add to dashboard Cite

Gut microbiome may influence tumor growth and cancer treatment efficacy, so it is a potential target for tumor prevention/treatment. This pilot study investigated the preventive and therapeutic effects of a probiotic strain, Lacticaseibacillus rhamnosus Probio-M9 (Probio-M9), against murine mammary cancer. Thirty-six female mice were randomly divided into three groups (n = 12 per group): control (without tumor transplantation), model (tumor transplantation; no probiotic administration), and probiotic (30-day oral gavage of probiotic, started seven days before tumor transplantation). Changes in tumor size were recorded, and blood, tumor tissue, and stool samples were collected at the end of the trial for analyses. Comparing with the model group, the probiotic group had a significantly smaller tumor volume (p < 0.05), a higher fecal microbiota Shannon diversity index, with significant modifications in the gut microbiota structure (p < 0.05), characterized by more Alistipes sp._2, Porphyromonadaceae bacterium_7, and Bacteroidales bacterium 55_9 (p < 0.05). Additionally, Probio-M9 administration elevated the serum IFN-γ, IL-9, IL-13, and IL-27 levels and several metabolites (e.g., pyridoxal, nicotinic acid, 3-hydroxybutyric acid, glutamine; p < 0.05), while reducing IL-5 (p < 0.05). These changes might be associated with the protective effect of Probio-M9 against mammary tumor growth. Thus, probiotic administration could harness host gut microbiome in anti-cancer responses.

show abstract

Section: Discussionmentioning

confidence: 99%

Lacticaseibacillus rhamnosus Probio-M9-Driven Mouse Mammary Tumor-Inhibitory Effect Is Accompanied by Modulation of Host Gut Microbiota, Immunity, and Serum Metabolome

Zhang

et al. 2022

Nutrients

Self Cite

View full text Add to dashboard Cite

show abstract

“…Probiotics are "live microorganisms which when administered in adequate amounts confer a health benefit on the host" 1 . Moreover, probiotics have been increasingly used in clinical settings in adjunct to conventional drugs for disease management [2][3][4][5][6][7] . However, there are potential safety concerns of probiotic use in patients with severe disease 8 .…”

Section: Introductionmentioning

confidence: 99%

Stronger gut microbiome modulatory effects by postbiotics than probiotics in a mouse colitis model

Zhang

Feng

et al. 2022

npj Sci Food

Self Cite

View full text Add to dashboard Cite

Probiotics are increasingly used as adjunctive therapy to manage gastrointestinal diseases, such as ulcerative colitis. However, probiotic use has posed some safety concerns. Thus, postbiotics are proposed as alternatives to probiotics in clinical applications. However, no study has directly compared the clinical benefits of probiotics and postbiotics. This study compared the beneficial effect of postbiotics and probiotics derived from the strain, Bifidobacterium adolescentis B8598, in a dextran sulfate sodium (DSS)-induced experimental colitis mouse model. Four groups of mice (n = 7 per group) were included in this work: Control (received water plus saline), DSS (received DSS without postbiotic/probiotic), Postbiotic (received DSS plus postbiotic), and Probiotic (received DSS plus probiotic). Our results showed that intragastric administration of both probiotic and postbiotic ameliorated colitis, reflected by decreased histology scores in Postbiotic and Probiotic groups compared with DSS group (P < 0.05). The fecal microbiota alpha diversity was not significantly affected by DSS-, postbiotic, or probiotic treatment. However, the postbiotic treatment showed stronger effects on modulating the fecal microbiota beta diversity, composition, and metagenomic potential than the probiotic treatment. Overall, our findings suggested that probiotics and postbiotics had similar ability to improve disease phenotype but had distinct ability to regulate the gut microbiota and metabolic pathways in the context of ulcerative colitis. In view of the smaller safety concern of postbiotics compared with probiotics and its stronger modulatory effect on the host gut microbiota, we propose that postbiotics are to be considered for use as next-generation biotherapeutics in managing ulcerative colitis or even other diseases.

show abstract

“…Bifidobacteria also yield probiotic strains with potential benefit in atherosclerosis. Patients with CAD were enrolled in a randomized, double-blind, placebo-controlled trial examining the efficacy of the probiotic strain Bifidobacterium lactis Probio-M8 in combination with conventional treatment involving lipid-lowering (atorvastatin) and β-blockade (metoprolol) [ 45 ]. Based on the study results, the study group reported significant improvement in anginal, anxiety, and depressive symptoms assessed through the Seattle Angina Questionnaire, Self-Rating Anxiety Scale, and the Self-Rating Depression Scale, respectively, compared to the control group.…”

Section: Current Therapeutic Interventionsmentioning

confidence: 99%

Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives

et al. 2023

View full text Add to dashboard Cite

The human gut microbiota is the community of microorganisms living in the human gut. This microbial ecosystem contains bacteria beneficial to their host and plays important roles in human physiology, participating in energy harvest from indigestible fiber, vitamin synthesis, and regulation of the immune system, among others. Accumulating evidence suggests a possible link between compositional and metabolic aberrations of the gut microbiota and coronary artery disease in humans. Manipulating the gut microbiota through targeted interventions is an emerging field of science, aiming at reducing the risk of disease. Among the interventions with the most promising results are probiotics, prebiotics, synbiotics, and trimethylamine N-oxide (TMAO) inhibitors. Contemporary studies of probiotics have shown an improvement of inflammation and endothelial cell function, paired with attenuated extracellular matrix remodeling and TMAO production. Lactobacilli, Bifidobacteria, and Bacteroides are some of the most well studied probiotics in experimental and clinical settings. Prebiotics may also decrease inflammation and lead to reductions in blood pressure, body weight, and hyperlipidemia. Synbiotics have been associated with an improvement in glucose homeostasis and lipid abnormalities. On the contrary, no evidence yet exists on the possible benefits of postbiotic use, while the use of antibiotics is not warranted, due to potentially deleterious effects. TMAO inhibitors such as 3,3-dimethyl-1-butanol, iodomethylcholine, and fluoromethylcholine, despite still being investigated experimentally, appear to possess anti-inflammatory, antioxidant, and anti-fibrotic properties. Finally, fecal transplantation carries conflicting evidence, mandating the need for further research. In the present review we summarize the links between the gut microbiota and coronary artery disease and elaborate on the varied therapeutic measures that are being explored in this context.

show abstract

Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes

Cited by 47 publications

References 63 publications

Lacticaseibacillus rhamnosus Probio-M9-Driven Mouse Mammary Tumor-Inhibitory Effect Is Accompanied by Modulation of Host Gut Microbiota, Immunity, and Serum Metabolome

Lacticaseibacillus rhamnosus Probio-M9-Driven Mouse Mammary Tumor-Inhibitory Effect Is Accompanied by Modulation of Host Gut Microbiota, Immunity, and Serum Metabolome

Stronger gut microbiome modulatory effects by postbiotics than probiotics in a mouse colitis model

Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives

Contact Info

Product

Resources

About